# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
NKGen Biotech shares are trading higher Monday after the company's SNK01 NK Cell Therapy was cleared to begin a Phase 2 tri...
PTCT: 27% | PTC Therapeutics Announces European Commission Returns Translarna Opinion to CHMP For Re-evaluation NKGN: 81% | NK...